Skip to main content

Table 3 The clinical outcomes of UI-EWD in tumor bleeding

From: Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding

Variables

Total enrolled patients

(n = 41)

UI-EWD monotherapy

(n = 23)

Success of Immediate hemostasis, n (%)

40 (97.5)

23 (100.0)

Cumulative re-bleeding, n (%)

9/40 (22.5)

6/23 (26.1)

At 7 day

3 (7.5)

1 (4.3)

At 28 days

9 (22.5)

6 (26.1)

At 180 days

9 (22.5)

6 (26.1)

Time to re-bleeding (day)§

10 (1–23)

12 (7–22)

RBC transfusion (unit)§

2 (0–6)

2 (0–6)

Hospital days§

10 (3–48)

10 (5–45)

After failure of hemostasis, method for treatment, n (%)

  

Embolization

1 (100.0)

0 (0.0)

Surgery

0 (0.0)

0 (0.0)

Conservative management

0 (0.0)

0 (0.0)

  1. RBC, red blood cell
  2. §, median (range)